Rapid ADME Filters for Lead Discovery

Molecular Interaction Fields: Applications in Drug Discovery and ADME Prediction

Volumn 27, Issue , 2006, Pages 249-272

  Oprea, Tudor I ^a   Benedetti, Paolo ^b   Berellini, Giuliano ^b   Olah, Marius ^c   Fejgin, Kim ^d   Boyer, Scott ^e  

^a Sunset Molecular Discovery LLC   (United States)

^b UNIVERSITY OF PERUGIA   (Italy)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e ASTRAZENECA R AND D   (Sweden)

Author keywords

Clinical pharmacokinetics and toxicological datasets; MIF based ADME models; Molecular interaction fields; Molecular interaction fields (MIFs); Rapid ADME filters for lead discovery; Rule of five (Ro5) as ADME filter; VolSurf

Indexed keywords

MOLECULAR STRUCTURE;

CLINICAL PHARMACOKINETICS; MOLECULAR INTERACTION FIELDS; RAPID ADME FILTERS FOR LEAD DISCOVERY; RULE OF FIVE (RO5) AS ADME FILTER; VOLSURF;

MOLECULAR INTERACTIONS;

EID: 85018236926     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/3527607676.ch11     Document Type: Chapter

References (64)

1. Austin, C. P., Brady, L. S., Insel, T. R., Collins, F. S. NIH molecular libraries initiative, Science 2004, 306, 1138-1139.
2. Drews, J. Innovation deficit revisited: Reflections on the productivity of pharmaceutical R & D, Drug Discov. Today 1998, 3, 491-494.
3. Horrobin, D. F. Innovation in the pharmaceutical industry, J. Royal Soc. Med. 2000, 93, 341-345.
4. Oprea, T. I. Virtual screening in lead discovery: A viewpoint, Molecules 2002, 7, 51-62.
5. Anonymous. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system, 2000. Available from http://www.fda.gov/cder/OPS/BCS_guidance.htm
6. Lipinski, C. A., Lombardo, F., Dominy, B.W., Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings, Adv. Drug Deliv. Rev. 1997, 23, 3-25.
7. Drews, J. Drug discovery: A historical perspective, Science 2000, 287, 1960-1964.
8. Van de Waterbeemd, H., Camenisch, G., Folkers, G., Raevsky, O. A. Estimation of Caco-2 cell permeability using calculated molecular descriptors, Quant. Struct.-Act. Relat. 1996, 15, 480-490.
9. Leo, A. Estimating LogPoct from structures, Chem. Rev. 1993, 93, 1281-1306. clogP is available from Daylight Chemical Information Systems, http://www.daylight.com
10. Lipinski, C. A. Druglike properties and the causes of poor solubility and poor permeability, J. Pharmacol. Toxicol. Methods, 2000, 44, 235-249.
11. Goodford, P. J. Computational procedure for determining energetically favourable binding sites on biologically important macromolecules, J. Med. Chem. 1985, 28, 849-857. GRID is available from Molecular Discovery Ltd, West Way House, Elms Parade, Oxford OX2 9LL, UK.
12. Taylor, N. R. Inhibition of sialidase, Meth. Princ. Med. Chem. 1998, 6, 105-119.
13. Von Itzstein, M., Wu, W.Y., Kok, G. B., Pegg, M. S., Dyason, J. C., Jin, B., Phan, T. V., Smythe, M. L., White, M. F., Oliver, S. W., Colman, P. M., Varghese, J. N., Ryan, D. M., Woods, J. M., Bethell, R. C., Hotham, V. J., Cameron, J. M., Penn, R. C. Rational design of potent sialidase-based inhibitors of influenza virus replication, Nature 1993, 363, 418-423.
14. Cruciani, G., Crivori, P., Carrupt, P. A., Testa, B. Molecular fields in quantitative structure-permeation relationships: The VolSurf approach, J. Mol. Struct. (Theochem) 2000, 503, 17-30. VolSurf is available from Molecular Discovery Ltd., http://moldiscovery.com
15. Wold, S., Johansson, E., Cocchi, M. PLS - partial least-squares projections to latent structures, in 3D QSAR in Drug Design: Theory, Methods and Applications, H Kubinyi, (ed.), ESCOM, Leiden, 1993, pp. 523-550.
16. Guba, W., Cruciani, G. Molecular field derived descriptors for the multivariate modeling of pharmacokinetic data, in Molecular Modeling and Prediction of Bioactivity, Gundertofte, K., Jørgensen, F. S. (eds.), Kluwer Academic/Plenum, New York, 2000, pp. 89-94.
17. Zamora, I., Oprea, T. I., Ungell, A. L. Prediction of oral drug permeability, in Rational Approaches to Drug Design, Höltje, H.D., Sippl, W. (eds.), Prous Science Press, Barcelona, 2001, pp. 271-280.
18. Crivori, P., Cruciani, G., Carrupt, P. A., Testa, B. Predicting blood-brain barrier permeation from three-dimensional molecular structure, J. Med. Chem. 2000, 43, 2204-2216.
19. Oprea, T. I., Zamora, I., Svensson, P. Quo vadis, scoring functions? Toward an integrated pharmacokinetic and binding affinity prediction framework, in Combinatorial Library Design and Evaluation for Drug Design, Ghose, A. K., Viswanadhan, V. N. (eds.), Marcel Dekker, New York, 2001, pp. 233-266.
20. Zamora, I., Oprea, T. I., Cruciani, G., Pastor, M., Ungell, A. L. Surface descriptors for protein-ligand affinity prediction, J. Med. Chem. 2003, 46, 25-33.
21. Davis, A. M., Riley, R. J. Predictive ADMET studies. The challenges and the opportunities, Curr. Opin. Chem. Biol. 2004, 8, 378-386.
22. Oprea, T. I. and Matter, H. Integrating virtual screening in lead discovery, Curr. Opin. Chem. Biol. 2004, 8, 349-358.
23. Williams, P. A., Cosme, J., Ward, A., Angove, H. C., Matak-Vinkovic, D., Jhoti, H. Crystal structure of human cytochrome P450 2C9 with bound warfarin, Nature 2003, 424, 464-468.
24. Zamora, I., Afzelius, L., Cruciani, G. Predicting drug metabolism: A site of metabolism prediction tool applied to the cytochrome P450 2C9, J. Med. Chem. 2003, 46, 2313-2324.
25. Afzelius, L., Zamora, I., Masimirembwa, C. M., Karlen, A., Andersson, T. B., Mecucci, S., Baroni, M., Cruciani, G. Conformer and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors, J. Med. Chem. 2004, 47, 907-914.
26. Boyer, S., Zamora, I. New methods in predictive metabolism, J. Comput.-Aided Mol. Design 2002, 16, 403-413.
27. Pastor, M., Cruciani, G., McLay, I., Pickett, S., Clementi, S. GRID-independent descriptors (GRIND): A novel class of alignment-independent three-dimensional molecular descriptors, J. Med. Chem. 2000, 43, 3233-3243.
28. Cruciani, G., Pastor, M., Clementi, S., Clementi, S. GRIND (GRID independent descriptors) in 3D structure metabolism relationships, in Rational Approaches to Drug Design, Höltje, H.D. and Sippl, W. (eds.), Prous Science Press, Barcelona, 2001, pp. 251-260.
29. Cruciani, G., Meniconi, M., Carosati, E., Zamora, I., Mannhold, R. VolSurf: A tool for drug ADME-properties prediction, in Drug Bioavailability, Methods and Principles in Medicinal Chemstry, Vol. 18, Van de Waterbeemd, H., Lennernäs, H., Artursson, P. (eds.), Wiley-VCH, Weinheim, 2003, pp. 406-419.
30. Artursson, P. Epithelial transport of drugs in cell culture. I. A model for studying the passive diffusion of drugs over intestinal absorptive (Caco-2) cells, J. Pharm. Sci. 1990, 79, 476-482.
31. Norinder, U., Haeberlein, M. Calculated molecular properties and multivariate statistical analysis in absorption prediction, in Drug Bioavailability, Methods and Principles in Medicinal Chemstry, Vol. 18, Van de Waterbeemd, H., Lennernäs, H., Artursson, P. (eds.), Wiley-VCH, Weinheim, 2003, pp. 358-405.
32. Abraham, M. H., Le, J. The correlation and prediction of the solubility of compounds in water using an amended solvation energy relationship, J. Pharm. Sci. 1999, 88, 868-880.
33. Huuskonen, J. Estimation of aqueous solubility for a diverse set of organic compounds based on molecular topology, J. Chem. Inf. Comput. Sci. 2000, 40, 773-777.
34. Meniconi, M. Solubility for potential drugs, theoretical and experimental methods. Laurea Thesis (M.Sc.), University of Perugia, Perugia, Italy, 2000.
35. Kratochwil, N. A., Huber, W., Muller, F., Kansy, M., Gerber, P. R. Predicting plasma protein binding of drugs: A new approach, Biochem. Pharmacol. 2002, 64, 1355-1374.
36. Lombardo, F., Obach, R., Scott, R., Shalaeva, M. Y., Gao, F. Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data, J. Med. Chem. 2002, 45, 2867-2876.
37. Lombardo, F., Obach, R., Scott, R., Shalaeva, M.Y., Gao, F. Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics, J. Med. Chem. 2004, 47, 1242-1250.
38. Vandenberg, J. I., Walker, B. D., Campbell, T. J. HERG K+ channels: Friend or foe, Trends Pharm. Sci. 2001, 22, 240-246.
39. Pearlstein, R., Vaz, R., Rampe, D. Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior, J. Med. Chem. 2003, 46, 2017-2022.
40. Pearlstein, R., Vaz, R., Kang, J., Chen, X. L., Preobrazhenskaya, M., Shchekotikhin, A. E., Korolev, A. M., Lysenkova, L. N., Miroshnikova, O.V., Hendrix, J., Rampe, D. Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches, Bioorg. Med. Chem. Lett. 2003, 13, 1829-1835.
41. Cavalli, A., Poluzzi, E., De Ponti, F., Recanatini, M. Toward a pharmacophore for drugs inducing the long QT syndrome: Insights from a CoMFA study of HERG K+ channel blockers, J. Med. Chem. 2002, 45, 3844-3853.
42. Roche, O., Trube, G., Zuegge, J., Pflimlin, P., Alanine, A., Schneider, G. A virtual screening method for prediction of the hERG potassium channel liability of compound libraries, ChemBioChem 2002, 3, 455-459.
43. Cianchetta, G., Li, Y., Kang, J., Rampe, D., Fravolini, A., Cruciani, G., Vaz, R. Predictive models for hERG potassium channel blockers, Bioorg. Med. Chem. Lett. 2005, 15, 3637-3642.
44. WOMBAT and WOMBAT-PK are available from Sunset Molecular Discovery LLC, http://www.sunsetmolecular.com
45. Hardman, J. G., Limbird, L. E., Molinoff, P. B., Ruddon, R.W., Gilman, A. G. Goodman & Gilman's the Pharmacological Basis of Therapeutics, 9th edn., McGraw Hill, New York, 1996.
46. Speight, T. M., Holford, N. H. G. Avery's Drug Treatment, 4th edn., Adis International, Auckland, 1997.
47. Anonymous. Physician Desk Reference, Thomson Healthcare, Montvale, 2001.
48. The FDA labels are at the CDER website, http://www.accessdata.fda.gov/scripts/cder/drugsatfda/
49. Contrera, J. F., Matthews, E. J., Kruhlak, N. L., Benz, R. D. Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose, Regulatory Toxicol. Pharmacol. 2004, 40, 185-206.
50. MRTD is available from the FDA website, http://www.fda.gov/cder/Offices/OPS_IO/MRTD.htm
51. Hansch, C., Leo, A., and Hoekman, D. Exploring QSAR, vol. 2, American Chemical Society, Washington, DC, 1995.
52. ACDLabs physchem suite is available from http://www.acdlabs.com
53. ALOGPS 2.1 is available from the Virtual Computational Chemistry Laboratory, http://vcclab.org
54. Oprea, T. I., Gottfries, J. Chemography: The art of chemical space navigation, J. Comb. Chem. 2001, 3, 157-166.
55. Oprea, T. I., Gottfries, J. Chem GPS: A chemical space navigation tool, in Rational Approaches to Drug Design, Holtje, H. D., Sippl, W. (eds.), Prous Science Press, Barcelona, 2001, pp. 437-446.
56. Sadowski, J., Kubinyi, H. A scoring scheme for discriminating between drugs and nondrugs, J. Med. Chem. 1998, 41, 3325-3329.
57. Ajay, Walters, W. P., Murcko, M. A. Can we learn to distinguish between "druglike" and "nondrug-like" molecules? J. Med. Chem. 1998, 41, 3314-3324.
58. Jackson, J. E. A users guide to principal components. Wiley-VCH, New York, 1991.
59. Clementi, S., Cruciani, G., Fifi, P., Riganelli, D., Valigi, R., Musumarra, G. A new set of principal properties for heteroaromatics obtained by GRID, Quant. Struct.-Act. Relat. 1996, 15, 108-120.
60. Sandberg, M., Eriksson, L., Jonsson, J., Sjöström, M., Wold, S. New chemical descriptors relevant for the design of biologically active peptides. A multivariate characterization of 87 amino acids, J. Med. Chem. 1998, 41, 2481-2491.
61. Lipinski, C. A., Hopkins, A. Navigating chemical space for biology and medicine, Nat. Rev. Drug Discov. 2004, 432, 855-861.
62. Oprea, T. I., Zamora, I., Ungell, A. L. Pharmacokinetically based mapping device for chemical space navigation, J. Comb. Chem. 2002, 4, 258-266.
63. The Pomona Masterfile is an extensive collection of experimental logP values, available from Albert Leo, Pomona College, California. http://clogp.pomona.edu
64. Oprea, T. I., Baroni, M., Zamora, I., Cruciani, G. High-throughput prediction of passive ADME properties from fragments, 224th ACS Natl. Meeting, Boston, MA, 2002, COMP-109. See http://moldiscovery.com for additional information.